No Data
No Data
Sinolink: The results of the negotiations on drug prices in the United States have been announced, and the continuous procurement of medical devices domestically is ongoing.
Bullish on the development of the domestic medical devices industry in the second half of the year, with the industry's purchasing demand expected to accelerate recovery. At the same time, domestic leading companies in sub-sectors such as ultrasound and endoscopy, due to their strong competitiveness, are expected to further increase market share, with sales growth and profitability expected to return to an upward trend.
Luye Pharma Sets Date for Financial Results Review
Luye Pharma (02186.HK) is planning to hold a board of directors meeting on August 28 to approve its mid-year performance.
Luye Pharma (02186.HK) announced on August 15th that the board of directors will hold a meeting on Wednesday, August 28th, 2024 to approve the interim performance of the company and its subsidiaries for the six months ending June 30, 2024, and to consider the distribution of interim dividends (if any).
LUYE PHARMA: NOTICE OF BOARD MEETING
Luye Pharma Group's Subsidiary's Investor Buys 25% Stake in Nanjing Luye for 1 Billion Yuan
Luye Pharma Group Completes Key Investment Phase
No Data